How has been the historical performance of Concord Drugs?

Answer:The historical performance of Concord Drugs shows a declining trend in net sales and profits over the past few years.

Breakdown:
Concord Drugs reported net sales of 45.25 Cr for the year ending March 2025, a slight increase from 44.93 Cr in March 2024, but a decrease from 52.09 Cr in March 2023 and 59.06 Cr in March 2022. The total operating income followed a similar pattern, remaining at 45.25 Cr in March 2025 compared to 44.93 Cr in March 2024, while it was higher in previous years. The total expenditure, excluding depreciation, was 41.11 Cr in March 2025, which is marginally higher than 40.88 Cr in March 2024 but lower than 47.50 Cr in March 2023 and 53.37 Cr in March 2022. Operating profit (PBDIT) was 4.14 Cr in March 2025, showing a slight increase from 4.05 Cr in March 2024, but down from 4.59 Cr in March 2023 and 5.69 Cr in March 2022. Profit before tax was 0.69 Cr in March 2025, up from 0.63 Cr in March 2024, but significantly lower than 1.25 Cr in March 2023 and 2.25 Cr in March 2022. The profit after tax also declined to 0.34 Cr in March 2025 from 0.47 Cr in March 2024, and it was notably higher in earlier years. The earnings per share dropped to 0.34 in March 2025 from 0.47 in March 2024, reflecting a downward trend from 1.06 in March 2023 and 1.82 in March 2022. Overall, the financial metrics indicate a consistent decline in performance over the years, particularly in profitability.